NOTE: 

To become a participant in one of our studies, Please ONLY click the Self-Referral Form below.
Click here to get a list of studies

that are Recruiting

Program for Depression based on severity of symptoms

Study Name: Comparing clinical decision-making of AI technology to a multi-professional care team in an e-CBT program for depression.

Description: If you believe you may be struggling with depression and you live in Ontario, you may be eligible to receive one of the following, depending on your symptoms and assessment:
-Online psychotherapy delivered by a trained psychotherapist
-Face-to-face psychotherapy
-A psychiatric consultation for medication management

e-CBT for Perimenopausal Anxiety

Study Name: Developing an Internet-Delivered Cognitive Behaviour Therapy Program for Women with Perimenopausal Anxiety: A Feasibility and Acceptability Study

Description: Participants in early menopause with Generalized Anxiety will engage in our e-CBT program, which includes elements of Acceptance and Commitment Therapy (ACT). Participants will receive personalized feedback from an care provider virtually, complete questionnaires to assess their mental health and menopause symptoms and will be invited to complete a post-study survey and take place in an optional semi-structured interview after completing the program.

Online Relapse  Prevention Psychotherapy for AUD

Study Name: Online Relapse Prevention Psychotherapy for Patients with Alcohol Use Disorder.

Description: Participants will  receive 10 weekly sessions focused on relapse prevention using cognitive behavioural therapy. The sessions will be delivered in an online or a video  format and participants will receive personalized feedback from a trained  therapist each week.

e-CBTi for insomnia

Study Name: Investigating the effectiveness of electronically delivered Cognitive Behavioural Therapy (e-CBTi) compared to Pharmaceutical Interventions in treating Insomnia.

Description: Participants will either receive e-CBTi program or will be prescribed trazodone (sleep medication) for the  duration of the study (7 weeks). Patients will receive personalized feedback.